Literature DB >> 7961997

Mutational analysis of vaccinia DNA topoisomerase defines amino acid residues essential for covalent catalysis.

J Wittschieben1, S Shuman.   

Abstract

The eukaryotic family of type I DNA topoisomerases includes the nuclear type I enzymes and the enzymes encoded by vaccinia and other poxviruses. The small size of the vaccinia topoisomerase (314 amino acids as compared to 765-972 amino acids for the cellular enzymes) makes it likely that this protein constitutes the minimal functional unit of a eukaryotic type I enzyme and provides an opportunity for a comprehensive structure-function analysis through mutagenesis. Two protein subregions were targeted for mutagenesis in the present study. The role of the Ser-Lys-X-X-Tyr sequence present at the active site of all family members was examined by replacing each conserved residue with alanine. Alanine substitution at the active site Tyr abrogated topoisomerase activity. In contrast, mutations at Ser-270 and Lys-271 had no effect on enzyme activity. The region of the vaccinia topoisomerase from amino acids 126-142 (MFFIRFGKMKYLKENET) is highly conserved and contains a residue, Gly-132, shown previously to be essential. Twenty-nine different mutations were generated in this region, with at least one substitution at each position. Point mutations were identified at three positions, Arg-130, Tyr-136, and Leu-137, which either abrogated or severely reduced DNA relaxation. The effects on activity could be attributed to a defect in formation of the covalent intermediate. Alterations of 13 other amino acids, including conserved residues, had little or no effect on topoisomerase activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961997

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Mechanism of DNA transesterification by vaccinia topoisomerase: catalytic contributions of essential residues Arg-130, Gly-132, Tyr-136 and Lys-167.

Authors:  J Wittschieben; S Shuman
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

2.  Mutational analysis of vaccinia virus topoisomerase identifies residues involved in DNA binding.

Authors:  J Sekiguchi; S Shuman
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

Review 3.  Probing enzyme phosphoester interactions by combining mutagenesis and chemical modification of phosphate ester oxygens.

Authors:  James T Stivers; Rajesh Nagarajan
Journal:  Chem Rev       Date:  2006-08       Impact factor: 60.622

4.  Chemical and traditional mutagenesis of vaccinia DNA topoisomerase provides insights to cleavage site recognition and transesterification chemistry.

Authors:  Lyudmila Yakovleva; Shengxi Chen; Sidney M Hecht; Stewart Shuman
Journal:  J Biol Chem       Date:  2008-03-25       Impact factor: 5.157

5.  DNA strand transfer reactions catalyzed by vaccinia topoisomerase: hydrolysis and glycerololysis of the covalent protein-DNA intermediate.

Authors:  B O Petersen; S Shuman
Journal:  Nucleic Acids Res       Date:  1997-06-01       Impact factor: 16.971

6.  Biochemical characterization of the topoisomerase domain of Methanopyrus kandleri topoisomerase V.

Authors:  Rakhi Rajan; Amy K Osterman; Alexandra T Gast; Alfonso Mondragón
Journal:  J Biol Chem       Date:  2014-08-18       Impact factor: 5.157

7.  Resolution of Holliday junctions by eukaryotic DNA topoisomerase I.

Authors:  J Sekiguchi; N C Seeman; S Shuman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

8.  Identification of contacts between topoisomerase I and its target DNA by site-specific photocrosslinking.

Authors:  J Sekiguchi; S Shuman
Journal:  EMBO J       Date:  1996-07-01       Impact factor: 11.598

9.  Diverse energetic effects of charge reversal mutations of poxvirus topoisomerase IB.

Authors:  Helen Jun; James T Stivers
Journal:  Biochemistry       Date:  2012-03-21       Impact factor: 3.162

10.  The genome of Melanoplus sanguinipes entomopoxvirus.

Authors:  C L Afonso; E R Tulman; Z Lu; E Oma; G F Kutish; D L Rock
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.